These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29445192)

  • 1. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
    Saini M; Verma A; Mathew SJ
    Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
    Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
    Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
    Miekus K; Lukasiewicz E; Jarocha D; Sekula M; Drabik G; Majka M
    Cell Death Dis; 2013 Jan; 4(1):e459. PubMed ID: 23328666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma.
    Annavarapu SR; Cialfi S; Dominici C; Kokai GK; Uccini S; Ceccarelli S; McDowell HP; Helliwell TR
    Lab Invest; 2013 Oct; 93(10):1090-9. PubMed ID: 23999248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
    Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
    J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
    Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
    Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
    Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
    Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation.
    Codenotti S; Faggi F; Ronca R; Chiodelli P; Grillo E; Guescini M; Megiorni F; Marampon F; Fanzani A
    Cancer Lett; 2019 May; 449():135-144. PubMed ID: 30771426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of invasion promoting genes in childhood rhabdomyosarcoma.
    Armeanu-Ebinger S; Bonin M; Häbig K; Poremba C; Koscielniak E; Godzinski J; Warmann SW; Fuchs J; Seitz G
    Int J Oncol; 2011 Apr; 38(4):993-1000. PubMed ID: 21271214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
    Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
    J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells.
    Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H
    Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.